Brief: Helix Biopharma accelerates escalation of L-DOS47 dosing in the U.S. Phase I study

Helix Biopharma

30/11/2016 12:30

Nov 30 (Reuters) - Helix Biopharma Corp  HBP.TO  
    * Helix Biopharma Corp accelerates escalation of L-DOS47 
dosing in the U.S. Phase I study 
    * Helix Biopharma -  U.S. FDA has accepted accelerated 
escalation for L-DOS47 dosing in U.S. Phase I study up to 
12g/kg in combination with pemetrexed/carboplatin 
 
Source text for Eikon:  ID:nCCN7HBZRx  
Further company coverage:  HBP.TO  
 
 ((Bangalore.newsroom@thomsonreuters.com;))